Shannon Maude MD
Pediatric Hematologic Oncology
Physician
Join to View Full Profile
3401 Civic Center BlvdChildren's Hospital Of Philadelphia - Hem/OncPhiladelphia, PA 19104
Phone+1 215-590-3535
Fax+1 215-590-3992
Dr. Maude is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2009 - 2012- Children's Hospital of PhiladelphiaResidency, Pediatrics, 2006 - 2009
Perelman School of Medicine at the University of PennsylvaniaClass of 2006
Certifications & Licensure
PA State Medical License 2006 - 2026
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL Start of enrollment: 2019 Jan 18
Publications & Presentations
PubMed
- Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies.Armin Ghobadi, Ibrahim Aldoss, Shannon L Maude, Deepa Bhojwani, Alan S Wayne
Blood. 2025-05-30 - CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.Regina M Myers, Amanda M DiNofia, Yimei Li, Caroline Diorio, Hongyan Liu
Journal for Immunotherapy of Cancer. 2025-04-17 - Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review.Connor B Grady, Yimei Li, Shannon L Maude, Elizabeth O Hexner, Noelle V Frey
Transplantation and Cellular Therapy. 2025-04-01
Journal Articles
- Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B CellVijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature
Abstracts/Posters
- Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell EfficacyShannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell TherapyShannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes60th American Society of Hematology Annual Meeting - 11/30/2018
Press Mentions
Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007December 5th, 2024- Researchers Use ‘Humanized’ CAR T Cells to Improve Treatment Durability for Patients with ALLSeptember 8th, 2021
- Durable Responses with CAR T-cell Retreatment in Young ALL PatientsJune 25th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
